Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 4/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19418192 | 0.84 | ALDH1A1 (0.42) | ALDH1A1KDM4EL3MBTL1CCNA2CDK2 | |
| SCHEMBL19418347 | 0.83 | ALDH1A1 (0.37) | ALDH1A1KDM4EL3MBTL1CCNA2CDK2 | |
| SCHEMBL27306012 | 0.83 | AR (0.52) | ALDH1A1KDM4EL3MBTL1JAK3JAK2 | |
| SCHEMBL31473419 | 0.82 | AR (0.39) | ALDH1A1KDM4EL3MBTL1HDAC6CYP19A1 | |
| SCHEMBL27297816 | 0.82 | AR (0.39) | ALDH1A1KDM4EL3MBTL1HDAC6CYP19A1 | |
| SCHEMBL27306293 | 0.82 | AR (0.40) | ALDH1A1KDM4EL3MBTL1CCNA2CDK2 | |
| SCHEMBL27305667 | 0.81 | AR (0.56) | ALDH1A1KDM4EL3MBTL1JAK3JAK2 | |
| SCHEMBL27305881 | 0.81 | JAK2 (0.42) | ALDH1A1KDM4EL3MBTL1CCNA2CDK2 | |
| SCHEMBL165008 | 0.81 | ALDH1A1 (0.46) | ALDH1A1KDM4EL3MBTL1CCNA2CDK2 | |
| SCHEMBL31473395 | 0.79 | SMN1; SMN2 (0.41) | ALDH1A1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042747-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ALIVEXIS, INC. (JP) | 2026-02-12 | — | — | US | disclosed |
| EP-4565575-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Alivexis, Inc. (JP) | 2025-06-11 | — | — | EP | disclosed |
| CN-119866333-A | KIT inhibitors, compounds, pharmaceutical compositions, and methods of use thereof | 亚力维克希斯股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| WO-2024029489-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MODULUS DISCOVERY, INC. (JP) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024029489-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MODULUS DISCOVERY, INC. (JP) | 2024-02-08 | — | — | WO | disclosed |
| WO-2010117662-A1 | MODULATORS OF S1P AND METHODS OF MAKING AND USING | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010117662-A1 | MODULATORS OF S1P AND METHODS OF MAKING AND USING | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100249071-A1 | Modulators of S1P and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249071-A1 | Modulators of S1P and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249071-A1 | Modulators of S1P and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249071-A1 | Modulators of S1P and Methods of Making And Using | S1PR5, S1PR1, S1PR2 | ALDH1A1 1654/4885KDM4E 1216/4885L3MBTL1 3241/4885 |
| US-20260042747-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KIT, LTK, HRH3 | ALDH1A1 1295/4885KDM4E 1369/4885L3MBTL1 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.